RADX Reports Q1 2026 Financials, RAD101 Interim Analysis Shows Promising Results

RADX's 1H:26 cash flow statement shows operating activities consumed ($22.7) million, while cash from financing activities was $33.4 million. The company held $34.5 million in cash as of December 31st, 2025, compared to $19.0 million at the end of FY:25. RAD101 Phase IIb interim analysis showed 92% (11/12) of evaluated patients achieved concordance with MRI imaging, with RAD202 cleared to move to the next dose level of 75 mCi in the HEAT trial.